Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Issued (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Shares Issued for 7 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 4480.72% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 51.75% increase, with the full-year FY2025 number at $4.2 million, up 51.75% from a year prior.
  • Shares Issued was $3.8 million for Q4 2025 at Fulcrum Therapeutics, up from $64000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $3.8 million in Q4 2025 to a low of -$2.7 million in Q4 2021.
  • A 5-year average of $622722.2 and a median of $294000.0 in 2023 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: crashed 104.26% in 2021, then skyrocketed 4480.72% in 2025.
  • Fulcrum Therapeutics' Shares Issued stood at -$2.7 million in 2021, then soared by 109.89% to $267000.0 in 2022, then rose by 7.49% to $287000.0 in 2023, then plummeted by 71.08% to $83000.0 in 2024, then surged by 4480.72% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Shares Issued are $3.8 million (Q4 2025), $64000.0 (Q3 2025), and $301000.0 (Q2 2025).